D Massi1, G Beltrami, R Capanna, A Franchi. 1. Department of Human Pathology and Oncology, University of Florence, Viale G.B. Morgagni 85, 50134 Florence, Italy.
Abstract
AIMS: The aims were to describe the clinico-pathological features of 65 patients affected by soft tissue pleomorphic sarcomas of the extremities, to evaluate their clinical outcome and to explore the prognostic impact of clinical and pathologic parameters, on disease-free and overall survival. METHODS: Soft tissue pleomorphic sarcomas of the extremities were retrieved to be retrospectively re-evaluated in the current analysis. The following parameters were analysed: age, sex, site, size, stage, histotype, grade, surgical margins, therapy. Disease-free and overall survival rates were calculated according to the Kaplan-Meier method. A multivariate analysis was used to determine which variable had an independent effect on clinical outcome. RESULTS: Sixty-five patients with soft tissue pleomorphic sarcomas of the extremities were included in the study. Upon revision, there were 22 leiomyosarcomas, 13 myxofibrosarcomas, 9 liposarcomas, 10 pleomorphic MFH/undifferentiated high grade pleomorphic sarcomas, and 11 cases were other types of plemorphic sarcomas, including rhabdomyosarcoma (n=4), osteosarcoma (n=2), myofibrosarcoma (n=5). In the whole series, by multivariate analysis, stage was the only factor predictor of disease progression (p=0.001; RR 6.9; 95% CI 1.3-15.6). Considering only localized pleomorphic sarcomas the independent predictors of disease relapse were site (p=0.03; RR 3.6; 95% CI 1.0-12.4) and myogenic differentiation (p=0.04; RR 2.9; 95% CI 0.9-10.0), whereas myogenic differentiation resulted the only independent predictor of overall survival (p=0.03; RR 6.5; 95% CI 1.1-37.9). DISCUSSION: These results indicate that histopathological classification of soft tissue pleomorphic sarcomas is clinically relevant. In our experience, AJCC stage and myogenic differentiation are the factors which independently affect prognosis.
AIMS: The aims were to describe the clinico-pathological features of 65 patients affected by soft tissue pleomorphic sarcomas of the extremities, to evaluate their clinical outcome and to explore the prognostic impact of clinical and pathologic parameters, on disease-free and overall survival. METHODS:Soft tissue pleomorphic sarcomas of the extremities were retrieved to be retrospectively re-evaluated in the current analysis. The following parameters were analysed: age, sex, site, size, stage, histotype, grade, surgical margins, therapy. Disease-free and overall survival rates were calculated according to the Kaplan-Meier method. A multivariate analysis was used to determine which variable had an independent effect on clinical outcome. RESULTS: Sixty-five patients with soft tissue pleomorphic sarcomas of the extremities were included in the study. Upon revision, there were 22 leiomyosarcomas, 13 myxofibrosarcomas, 9 liposarcomas, 10 pleomorphic MFH/undifferentiated high grade pleomorphic sarcomas, and 11 cases were other types of plemorphic sarcomas, including rhabdomyosarcoma (n=4), osteosarcoma (n=2), myofibrosarcoma (n=5). In the whole series, by multivariate analysis, stage was the only factor predictor of disease progression (p=0.001; RR 6.9; 95% CI 1.3-15.6). Considering only localized pleomorphic sarcomas the independent predictors of disease relapse were site (p=0.03; RR 3.6; 95% CI 1.0-12.4) and myogenic differentiation (p=0.04; RR 2.9; 95% CI 0.9-10.0), whereas myogenic differentiation resulted the only independent predictor of overall survival (p=0.03; RR 6.5; 95% CI 1.1-37.9). DISCUSSION: These results indicate that histopathological classification of soft tissue pleomorphic sarcomas is clinically relevant. In our experience, AJCC stage and myogenic differentiation are the factors which independently affect prognosis.
Authors: Pawel Kurzawa; John T Mullen; Yen-Lin Chen; Sarah E Johnstone; Vikram Deshpande; Ivan Chebib; G P Nielsen Journal: Am J Surg Pathol Date: 2020-06 Impact factor: 6.394
Authors: Ann Y Lee; Narasimhan P Agaram; Li-Xuan Qin; Deborah Kuk; Christina Curtin; Murray F Brennan; Samuel Singer Journal: Ann Surg Oncol Date: 2016-01-12 Impact factor: 5.344
Authors: Abbas Agaimy; Andreas Gaumann; Josef Schroeder; Wolfgang Dietmaier; Arndt Hartmann; Ferdinand Hofstaedter; Peter H Wünsch; Thomas Mentzel Journal: Virchows Arch Date: 2007-09-14 Impact factor: 4.064
Authors: Elai Davicioni; Michael J Anderson; Friedrich Graf Finckenstein; James C Lynch; Stephen J Qualman; Hiroyuki Shimada; Deborah E Schofield; Jonathan D Buckley; William H Meyer; Poul H B Sorensen; Timothy J Triche Journal: Am J Pathol Date: 2009-01-15 Impact factor: 4.307
Authors: Ronald S A de Vreeze; Daphne de Jong; Petra M Nederlof; Aafke Ariaens; Ivon H G Tielen; Luc Frenken; Rick L Haas; Frits van Coevorden Journal: Ann Surg Oncol Date: 2010-03 Impact factor: 5.344
Authors: Elizabeth G Demicco; Genevieve M Boland; Kari J Brewer Savannah; Kristelle Lusby; Eric D Young; Davis Ingram; Kelsey L Watson; Marshall Bailey; Xiangqian Guo; Jason L Hornick; Matt van de Rijn; Wei-Lien Wang; Keila E Torres; Dina Lev; Alexander J Lazar Journal: Histopathology Date: 2015-01-12 Impact factor: 5.087